Gilead Sciences Inc.

60.38-0.1900-0.31%Vol 3.93M1Y Perf -6.95%
Oct 20th, 2020 13:08 DELAYED
BID60.38 ASK60.39
Open60.59 Previous Close60.57
Pre-Market60.65 After-Market60.57
 0.08 0.13%  - -%
Target Price
80.26 
Analyst Rating
Moderate Buy 2.48
Potential %
32.90 
Finscreener Ranking
★★★+     53.19
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     63.86
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     63.68
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★★★     58.06
Market Cap75.70B 
Earnings Rating
Buy
Price Range Ratio 52W %
2.03 
Earnings Date
28th Oct 2020

Today's Price Range

59.8560.68

52W Range

59.8585.97

5 Year PE Ratio Range

5.9025.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-6.08%
1 Month
-6.89%
3 Months
-22.43%
6 Months
-25.46%
1 Year
-6.95%
3 Years
-25.42%
5 Years
-40.16%
10 Years
217.94%

TickerPriceChg.Chg.%
GILD60.38-0.1900-0.31
AAPL118.322.34002.02
GOOG1 552.4717.86001.16
MSFT215.541.32000.62
XOM33.740.32000.96
WFC22.860.32001.42
JNJ145.130.81000.56
FB267.536.13002.35
GE7.360.07000.96
JPM101.171.37001.37
Financial StrengthValueIndustryS&P 500US Markets
2.80
3.40
0.50
1.09
5.90
Leverage Ratio 2.70
ProfitabilityValueIndustryS&P 500US Markets
79.40
25.50
31.60
46.50
18.18
RevenueValueIndustryS&P 500US Markets
17.03B
13.58
-9.66
-8.37
DividendsValueIndustryS&P 500US Markets
4.49
2.72
8.18
25.16
Payout ratio65.00
Earnings HistoryEstimateReportedSurprise %
Q02 20201.461.11-23.97
Q01 20201.471.6814.29
Q04 20191.581.10-30.38
Q03 20191.661.65-0.60
Q02 20191.681.722.38
Q01 20191.531.679.15
Q04 20181.611.34-16.77
Q03 20181.561.708.97
Earnings Per EndEstimateRevision %Trend
9/2020 QR1.8714.02Positive
12/2020 QR2.1927.33Positive
12/2020 FY6.841.63Positive
12/2021 FY7.214.64Positive
Next Report Date28th Oct 2020
Estimated EPS Next Report1.87
Estimates Count11
EPS Growth Next 5 Years %13.10
Volume Overview
Volume3.93M
Shares Outstanding1.25B
Trades Count43.23K
Dollar Volume251.41M
Avg. Volume14.67M
Avg. Weekly Volume8.48M
Avg. Monthly Volume8.22M
Avg. Quarterly Volume8.94M

Gilead Sciences Inc. (NASDAQ: GILD) stock closed at 60.57 per share at the end of the most recent trading day (a -2.31% change compared to the prior day closing price) with a volume of 9.64M shares and market capitalization of 75.70B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11000 people. Gilead Sciences Inc. CEO is Daniel O¿Day.

The one-year performance of Gilead Sciences Inc. stock is -6.95%, while year-to-date (YTD) performance is -6.79%. GILD stock has a five-year performance of -40.16%. Its 52-week range is between 59.85 and 85.97, which gives GILD stock a 52-week price range ratio of 2.03%

Gilead Sciences Inc. currently has a PE ratio of 17.90, a price-to-book (PB) ratio of 4.31, a price-to-sale (PS) ratio of 4.46, a price to cashflow ratio of 8.50, a PEG ratio of 2.32, a ROA of 8.17%, a ROC of 11.99% and a ROE of 22.76%. The company’s profit margin is 18.18%, its EBITDA margin is 31.60%, and its revenue ttm is $17.03 Billion , which makes it $13.58 revenue per share.

Of the last four earnings reports from Gilead Sciences Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $1.87 for the next earnings report. Gilead Sciences Inc.’s next earnings report date is 28th Oct 2020.

The consensus rating of Wall Street analysts for Gilead Sciences Inc. is Moderate Buy (2.48), with a target price of $80.26, which is +32.90% compared to the current price. The earnings rating for Gilead Sciences Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Gilead Sciences Inc. has a dividend yield of 4.49% with a dividend per share of $2.72 and a payout ratio of 65.00%.

Gilead Sciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.33, ATR14 : 1.37, CCI20 : -212.00, Chaikin Money Flow : -0.27, MACD : -0.78, Money Flow Index : 44.71, ROC : -2.57, RSI : 33.58, STOCH (14,3) : 7.72, STOCH RSI : 0.00, UO : 39.18, Williams %R : -92.28), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Gilead Sciences Inc. in the last 12-months were: Andrew Dickinson (Option Excercise at a value of $0), Brett A. Pletcher (Option Excercise at a value of $3 845 530), Brett A. Pletcher (Sold 167 038 shares of value $11 289 940 ), Daniel O'Day (Option Excercise at a value of $0), Diane E. Wilfong (Option Excercise at a value of $762 211), Diane E. Wilfong (Sold 12 264 shares of value $982 220 ), Gayle E. Wilson (Option Excercise at a value of $852 727), Gayle E. Wilson (Sold 43 440 shares of value $2 941 756 ), Harish Manwani (Option Excercise at a value of $0), Javier J. Rodriguez (Sold 378 shares of value $28 539 ), Johanna Mercier (Option Excercise at a value of $0), John F. Cogan (Option Excercise at a value of $852 727), John F. Cogan (Sold 43 440 shares of value $3 359 000 ), Kevin E. Lofton (Option Excercise at a value of $852 727), Merdad Parsey (Sold 182 shares of value $12 434 ), Per Wold-Olsen (Option Excercise at a value of $1 690 171), Per Wold-Olsen (Sold 84 004 shares of value $5 758 126 ), Richard J. Whitley (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (28.57 %)
6 (27.27 %)
9 (40.91 %)
Moderate Buy
1 (4.76 %)
1 (4.55 %)
2 (9.09 %)
Hold
13 (61.90 %)
13 (59.09 %)
10 (45.45 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (4.76 %)
2 (9.09 %)
1 (4.55 %)
Summary RatingModerate Buy
2.48
Hold
2.59
Moderate Buy
2.18

Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.

CEO: Daniel O¿Day

Teplephone: +1 650 574-3000

Address: 333 Lakeside Drive, Foster City 94404, CA, USA

Number of employees: 11 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

20%80%

Bearish Bullish

56%44%

Bearish Bullish

49%51%

Bearish Bullish

58%42%

News

Stocktwits